Evaluación positiva de medicamentos3.er trimestre 2012
- M.A. Cabanes Mariscal
- P. Sánchez López
- M. Puerro Vicente
- A. García Luque
ISSN: 1887-8571
Argitalpen urtea: 2012
Alea: 68
Zenbakia: 4
Orrialdeak: 234-237
Mota: Artikulua
Beste argitalpen batzuk: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España
Laburpena
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the third quarter of 2012, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.
Erreferentzia bibliografikoak
- Informe mensual sobre medicamentos de Uso Humano y Productos Sanitario.
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP).
- Eylea.
- Aprovell labell Eylea.
- Aprovell labell Eylea.
- Informe mensual sobre medicamentos de Uso Humano y Productos Sanitarios.
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP).
- Adcetris.
- Stephanie, S, Minich. (2012). Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Ann Pharmacother March. 46. 377-383
- NexoBrid.
- Xalkori.
- Aprovell labell Xalkori.
- Dacogen.
- Aprovell labell Dacogen.
- Picato.
- Aprovell Labell Picato.
- Constella.
- Aprovell labell Constella.
- Anthony, J, Lembo, M.D., Harvey, A., Schneier, M.D.. (2011). Two Randomized Trials of Linaclotide for Chronic Constipacion. N England J Med. 365. 527-536